http://purl.org/np/RA_oI-ncugFmT2Sae4sIvA5x79B79QFxBP8K68MO35Gbs
.trig | .trig.txt | .jelly | .jelly.txt
@prefix this: <http://purl.org/np/RA_oI-ncugFmT2Sae4sIvA5x79B79QFxBP8K68MO35Gbs> . @prefix sub: <http://purl.org/np/RA_oI-ncugFmT2Sae4sIvA5x79B79QFxBP8K68MO35Gbs#> . @prefix np: <http://www.nanopub.org/nschema#> . @prefix pav: <http://purl.org/pav/> . @prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> . @prefix infores: <https://w3id.org/biolink/infores/> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . @prefix umls: <http://identifiers.org/umls/> . @prefix orcid: <https://orcid.org/> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix biolink: <https://w3id.org/biolink/vocab/> . @prefix prov: <http://www.w3.org/ns/prov#> . @prefix unii: <http://identifiers.org/unii/> . @prefix npx: <http://purl.org/nanopub/x/> . sub:Head { this: a np:Nanopublication; np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo . } sub:assertion { umls:C1299487 a biolink:OrganismTaxon; rdfs:label "patients"; biolink:category biolink:OrganismTaxon . unii:0K47UL67F2 a biolink:ChemicalEntity; rdfs:label "Carvedilol"; biolink:category biolink:ChemicalEntity . <http://purl.obolibrary.org/obo/CHEBI_50264> a biolink:ChemicalEntity; rdfs:label "thiazide"; biolink:category biolink:ChemicalEntity . <http://purl.obolibrary.org/obo/MONDO_0005068> a biolink:DiseaseOrPhenotypicFeature; rdfs:label "myocardial infarction"; biolink:category biolink:DiseaseOrPhenotypicFeature . sub:_1 a biolink:Association; rdf:object <http://purl.obolibrary.org/obo/CHEBI_50264>; rdf:predicate biolink:treated_by; rdf:subject <http://purl.obolibrary.org/obo/MONDO_0005068>; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> . sub:_2 a biolink:Association; rdf:object <http://purl.obolibrary.org/obo/CHEBI_50264>; rdf:predicate biolink:treats; rdf:subject unii:0K47UL67F2; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> . sub:_3 a biolink:Association; rdf:predicate biolink:treats; rdf:subject unii:0K47UL67F2; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> . sub:_4 a biolink:Association; rdf:predicate biolink:treats; rdf:subject unii:0K47UL67F2; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> . sub:_5 a biolink:Association; rdf:object <http://purl.obolibrary.org/obo/CHEBI_50264>; rdf:predicate biolink:treated_by; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> . sub:_6 a biolink:Association; rdf:object <http://purl.obolibrary.org/obo/MONDO_0005068>; rdf:predicate biolink:treats; rdf:subject unii:0K47UL67F2; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> . } sub:provenance { sub:assertion prov:generatedAtTime "2022-10-11T07:14:02.124516"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627; prov:wasQuotedFrom " Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40%. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. It is indicated for the management of essential. essential. heart failure." . biolink: pav:version "2.3.0" . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB"; npx:hasSignature "U/r65UOfFROfafNoL599E6jgtio6BnZAIOQ1yWdFWz31jXT3rO1XdUkfRnFBq0DJBvvLCK6Kgx3dPyzLSxzt4c9/yLUpeWGwA2P6nHElBdOI3E2TPwHNUPGoPM7kjPyL2Jvb6GbpBIpfxJ1oDg7V3VISyL+TYzo8C4zyPsuOawgFdwpv5GRmVcxQikIyseagaWl8jyXG8m67wo16NoNUUoT4UACC70paz+bzcSlgcVxCe4y5TL+nXAzUCM9T8KvBMe714vlQ8/duaRBOhT2Qy0N6qB5gdFeDOWCqvH3VFUtSqqaEQSrrIFvOCO3Ydiuu8DRsmg69hVheB/qGTG5vUA=="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-10-11T07:14:02.124516"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627 . }